1.21

4.31% 0.05

Adc Therapeutics Sa (ADCT)

Overview News Price History Option Chain Discussions Forecast

Adc Therapeutics Sa stock is traded at $1.21, with a volume of 165.66K. It is up +4.31% in the last 24 hours and down -32.40% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Previous Close:

$1.16

Open:

$1.16

24h Volume:

165.66K

Relative Volume:

0.43

Market Cap:

$119.89M

Revenue:

$69.56M

Net Income/Loss:

$-240.05M

P/E Ratio:

-0.4102

EPS:

-2.95

Net Cash Flow:

$-121.90M

1W Performance:

+8.04%

1M Performance:

-32.40%

6M Performance:

-61.46%

1Y Performance:

-75.60%

1-Day Range:

$1.14

$1.24

1-Week Range:

$1.10

$1.25

52-Week Range:

$1.05

$5.17

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name

Adc Therapeutics Sa

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

41 21 653 02 00

Address

BIOPOLE, EPALINGES

Employee

263

Twitter

Next Earnings Date

2025-03-21

Latest SEC Filings

ADCT's Discussions on Twitter

Compare ADCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADCT Adc Therapeutics Sa	1.21	119.89M	69.56M	-240.05M	-121.90M	-2.95
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-06-22	Initiated	CapitalOne	Overweight
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-21	Initiated	Wolfe Research	Outperform
Aug-17-21	Resumed	Jefferies	Buy
Aug-09-21	Initiated	RBC Capital Mkts	Outperform
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight
Dec-03-20	Initiated	Stifel	Hold
Oct-29-20	Initiated	H.C. Wainwright	Buy
Jun-09-20	Initiated	BofA/Merrill	Buy
Jun-09-20	Initiated	Cowen	Outperform

View All

Adc Therapeutics Sa Stock (ADCT) Latest News

Apr 16, 2025

Antibody Drug Conjugate Market to Witness Upsurge in Growth - openPR.com

Apr 16, 2025

Apr 15, 2025

Wellington Management Group LLP Purchases 84,785 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World

Apr 15, 2025

Apr 13, 2025

ADC Therapeutics : Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting - marketscreener.com

Apr 13, 2025

Sei Investments Co. Invests $46,000 in ADC Therapeutics SA (NYSE:ADCT) - The AM Reporter

Apr 13, 2025

Sei Investments Co. Makes New $46,000 Investment in ADC Therapeutics SA (NYSE:ADCT) - Defense World

Apr 13, 2025

Apr 12, 2025

Prudential Financial Inc. Invests $35,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World

Apr 12, 2025

Apr 09, 2025

ADC Therapeutics : 24th Annual Needham Virtual Healthcare Conference - MarketScreener

Apr 08, 2025

Apr 07, 2025

Analyzing Ratios: Adc Therapeutics SA (ADCT)’s Financial Story Unveiled - DWinneX

Apr 07, 2025

ADC Therapeutics SA (NYSE:ADCT) Sees Large Decline in Short Interest - MarketBeat

Apr 07, 2025

Apr 04, 2025

Research Analysts Set Expectations for ADCT Q1 Earnings - Defense World

Apr 04, 2025

Burkitt Lymphoma Market Expected to Witness Significant Growth by 2032 | DelveInsight - The Globe and Mail

Apr 04, 2025

ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st

Apr 04, 2025

NBE Therapeutics opens ADC research facility in Switzerland - Pharmaceutical Technology

Apr 04, 2025

Apr 03, 2025

ADC Therapeutics' (ADCT) Buy Rating Reiterated at HC Wainwright - MarketBeat

Apr 03, 2025

ADC Therapeutics (NYSE:ADCT) Given New $7.00 Price Target at Guggenheim - MarketBeat

Apr 03, 2025

ADCT Stock Touches 52-Week Low at $1.61 Amid Market Challenges - MSN

Apr 03, 2025

Apr 02, 2025

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Malaysian Reserve

Apr 02, 2025

Apr 01, 2025

ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results - MarketBeat

Apr 01, 2025

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire

Apr 01, 2025

ADC Therapeutics Strengthens Team with Major Equity Incentive Package - Stock Titan

Apr 01, 2025

ADC Therapeutics (NYSE:ADCT) Given “Buy” Rating at HC Wainwright - Defense World

Apr 01, 2025

ADC Therapeutics (NYSE:ADCT) Price Target Lowered to $7.00 at Guggenheim - Defense World

Apr 01, 2025

Mar 31, 2025